HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes.

Abstract
Botulinum toxin (BoNT) is highly effective in the treatment of cervical dystonia (CD), yet a significant proportion of patients report low levels of satisfaction following treatment and fail to follow up for repeated treatments. The goal of this study was to determine the reasons that some patients have unsatisfactory responses. A total of 35 subjects who came to our center requesting alternative treatments due to unsatisfactory responses following BoNT treatment for CD were evaluated. Included were 26 women and 9 men with an average age of 57.1 years (range 25-82 years), and an average duration of illness of 12.5 years (range 1-55 years). Details of unsatisfactory BoNT treatments were methodically collected by a movement specialist using a standardized intake form, including provider subspecialty, product used, the number of satisfactory or unsatisfactory trials, doses given, specific muscles treated, the use of electromyographic guidance, side effects, and tests of resistance. The specialist then provided repeat treatments if indicated, and followed each case until the reasons for unsatisfactory outcomes could be determined. Multiple reasons for unsatisfactory outcomes were found. They included suboptimal BoNT doses, suboptimal muscle targeting, intolerable side effects, complex movement patterns, discordant perceptions, and incorrect diagnoses. Only one patient was functionally resistant to BoNT. Of 32 subjects who received repeat BoNT treatments, 25 (78 %) achieved satisfactory responses after revision of the original treatment plan. These results indicate that the majority of unsatisfactory responses to BoNT treatment of CD were caused by correctible factors and imply a need for improved education regarding optimal treatment methods.
AuthorsH A Jinnah, Emily Goodmann, Ami R Rosen, Marian Evatt, Alan Freeman, Stewart Factor
JournalJournal of neurology (J Neurol) Vol. 263 Issue 6 Pg. 1188-94 (Jun 2016) ISSN: 1432-1459 [Electronic] Germany
PMID27113604 (Publication Type: Journal Article)
Chemical References
  • Acetylcholine Release Inhibitors
  • Botulinum Toxins, Type A
Topics
  • Acetylcholine Release Inhibitors (adverse effects, therapeutic use)
  • Adult
  • Aged
  • Aged, 80 and over
  • Botulinum Toxins, Type A (adverse effects, therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Resistance
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Satisfaction
  • Prospective Studies
  • Torticollis (drug therapy, psychology)
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: